izpis_h1_title_alt

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
Jaklič, Alenka (Avtor), Collins, Carol J. (Avtor), Mrhar, Aleš (Avtor), Sorror, Mohamed L. (Avtor), Sandmaier, Brenda M. (Avtor), Bemer, Meagan J. (Avtor), Locatelli, Igor (Avtor), McCune, Jeannine S. (Avtor)

URLURL - Predstavitvena datoteka, za dostop obiščite http://www.dustri.com/index.php?id=98&artId=10704 Povezava se odpre v novem oknu

Izvleček
Objective: Mycophenolic acid (MPA) exposure is associated with clinical outcomes in hematopoietic cell transplant (HCT) recipients. Various drug interaction studies, predominantly in healthy volunteers or solid organ transplant recipients, have identified medications which impact MPA pharmacokinetics. Recipients of nonmyeloablative HCT, however, have an increased burden of comorbidities, potentially increasing the number of concomitant medications and potential drug interactions (PDI) affecting MPA exposure. Thus, we sought to be the first to characterize these PDI in nonmyeloablative HCT recipients. Materials and methods: We compiled PDI affecting MPA pharmacokinetics and characterized the prevalence of PDI in nonmyeloablative HCT recipients. A comprehensive literature evaluation of fourdatabases and PubMed was conducted to identify medications with PDI affectng MPA pharmacokinetics. Subsequently, a retrospective medication review was conducted to characterize the cumulative PDI burden, defined as the number of PDI for an individual patient over the first 21 days after allogeneic graft infusion, in 84 nonmyeloablative HCT recipients. Results: Of the 187 concomitant medications, 11 (5.9%) had a PDI affecting MPA pharmacokinetics. 87% of 84 patients had one PDI, with a median cumulative PDI burden of 2 (range 0 - 4). The most common PDI, in descending order, were cyclosporine, omeprazole and pantoprazole. Conclusion: Only a minority of medications (5.9%) have a PDI affecting MPA pharmacokinetics. However, the majority of nonmyeloablative HCT recipients had a PDI, with cyclosporine and the proton pump inhibitors being the most common. A better understanding of PDI and their management should lead to safer medication regimens for nonmyeloablative HCT recipients.

Jezik:Angleški jezik
Ključne besede:farmakokinetika, medsebojno delovanje zdravil, transplantacija organov, izvorne celice, protonska črpalka, ciklosporin
Vrsta gradiva:Delo ni kategorizirano (r6)
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Leto izida:2013
Št. strani:str. 711-717
Številčenje:Vol. 51, no. 9
UDK:615.1.015
ISSN pri članku:0946-1965
DOI:10.5414/CP201884 Povezava se odpre v novem oknu
COBISS.SI-ID:3489649 Povezava se odpre v novem oknu
Število ogledov:499
Število prenosov:206
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
 
Skupna ocena:(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
:
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Gradivo je del revije

Naslov:International journal of clinical pharmacology and therapeutics
Skrajšan naslov:Int. j. clin. pharmacol. ther.
Založnik:Dustri-Verl. Feistle
ISSN:0946-1965
COBISS.SI-ID:161137 Povezava se odpre v novem oknu

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj